Studies Highlight Utility of Virologic Assays in HIV Management at 12th Conference on Retroviruses and Opportunistic Infections
28 February 2005 - 11:45PM
PR Newswire (US)
Studies Highlight Utility of Virologic Assays in HIV Management at
12th Conference on Retroviruses and Opportunistic Infections SOUTH
SAN FRANCISCO, Calif., Feb. 28 /PRNewswire-FirstCall/ -- ViroLogic,
Inc. (NASDAQ:VLGC) announced today that 20 presentations related to
its sophisticated tests characterizing replication capacity (RC),
viral tropism, and phenotypic and genotypic resistance to anti-HIV
drugs were made at the 12th Conference on Retroviruses and
Opportunistic Infections (CROI), which took place this week in
Boston. "These studies highlight the importance of ViroLogic's
tests for resistance, RC and tropism in the effective management of
HIV patients and the development of new HIV drugs and vaccines,"
stated Christos Petropoulos, Ph.D., Vice President of Research and
Development at ViroLogic. "ViroLogic is expanding the field of
knowledge about HIV and is the collaboration partner of choice for
pharmaceutical companies and researchers." Among the highlights of
this year's presentations: * Two studies used ViroLogic's RC assay
to assess the role of viral fitness in HIV disease progression
during antiretroviral therapy. These studies evaluated the use of
the RC assay as a predictor of immune system recovery; * Seven
presentations included data generated using ViroLogic's proprietary
entry susceptibility and co-receptor tropism assays, which measure
viral susceptibility to entry inhibitors, and identify the
preferred cell receptors for HIV for virus entry, respectively.
Several of these studies show ViroLogic's expanding capability to
support the numerous biopharmaceutical companies now developing
entry inhibitor drugs to treat HIV; and * Six presentations used
ViroLogic's PhenoSense GT(TM), PhenoSense(TM) HIV and GeneSeq(TM)
HIV assays to further our understanding of resistance to a number
of current drugs and to determine the clinical utility of combined
resistance testing in the selection of antiretroviral regimens.
About ViroLogic ViroLogic is a biotechnology company advancing
individualized medicine by discovering, developing and marketing
innovative products to guide and improve treatment of serious
infectious diseases and cancer. The Company's products are designed
to help doctors optimize treatment regimens for their patients that
lead to better outcomes and reduced costs. The Company's technology
is also being used by numerous biopharmaceutical companies to
develop new and improved antiviral therapeutics and vaccines as
well as targeted cancer therapeutics. More information about the
Company and its technology can be found on its web site at
http://www.virologic.com/. FORWARD LOOKING STATEMENTS Certain
statements in this press release are forward-looking, including
statements regarding the role for ViroLogic's tests and tests in
development in guiding the therapy of HIV-infected patients. These
forward-looking statements are subject to risks and uncertainties
and other factors, which may cause actual results to differ
materially from the anticipated results or other expectations
expressed in such forward-looking statements. These risks and
uncertainties include, but are not limited to, risks and
uncertainties relating to the performance of our products; our
ability to successfully conduct clinical studies and the results
obtained from those studies; whether larger confirmatory clinical
studies will confirm the results of initial studies; our ability to
establish reliable, high-volume operations at commercially
reasonable costs; expected reliance on a few customers for the
majority of our revenues; the annual renewal of certain customer
agreements; actual market acceptance of our products and adoption
of our technological approach and products by pharmaceutical and
biotechnology companies; our estimate of the size of our markets;
our estimates of the levels of demand for our products; the timing
and ultimate size of pharmaceutical company clinical trials;
whether payors will authorize reimbursement for its products;
whether the FDA or any other agency will decide to regulate
ViroLogic's products or services; whether the Company will
encounter problems or delays in automating its processes; whether
intellectual property underlying the Company's technologies is
adequate; whether licenses to third party technology will be
available; and, whether we are able to build brand loyalty and
expand revenues. For a discussion of other factors that may cause
ViroLogic's actual events to differ from those projected, please
refer to the Company's most recent annual report on Form 10-K and
quarterly reports on Form 10-Q, as well as other subsequent filings
with the Securities and Exchange Commission. DATASOURCE: ViroLogic,
Inc. CONTACT: Alfred Merriweather, Vice President and CFO of
ViroLogic, +1-650-635 -1100; or Carolyn Bumgardner Wang of
WeissComm Partners, +1-415-692-4218, or , for ViroLogic Web site:
http://www.virologic.com/
Copyright
Virologic (NASDAQ:VLGC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Virologic (NASDAQ:VLGC)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Virologic (MM) (NASDAQ): 0 recent articles
More Virologic (MM) News Articles